News & Press Releases

Exact Imaging Reports Strong Momentum Driven by Commercial Execution and Clinical Validation in 2025

New sales model, expanded evidence base, NCCN guideline inclusion, and growing customer adoption reinforce the value of the ExactVu™ micro-ultrasound platform

MARKHAM, Ontario – January 30, 2026 – Exact Imaging, a global leader in high-resolution micro-ultrasound systems for prostate cancer, today reported strong business momentum in calendar year 2025, reflecting progress across commercial execution, clinical validation, and market adoption.

Micro-ultrasound with ExactVu Proven Non-Inferior to MRI for Prostate Cancer Diagnosis in OPTIMUM Randomized Trial

Study data, published in JAMA and presented at EMUC 2025, suggest ExactVu is potential MRI alternative for image-guided prostate biopsy

MARKHAM, Ontario – November 17, 2025 – Exact Imaging today announced that results from its OPTIMUM clinical trial demonstrating the non-inferiority of its ExactVu™ micro-ultrasound platform to MRI fusion-guided biopsy for diagnosing prostate cancer were presented on Nov. 14 by Dr. Laurence Klotz at the European Multidisciplinary Congress on Urological Cancers (EMUC) in Prague. Also published in JAMA, the study data suggest that ExactVu could provide an alternative to MRI for image-guided prostate biopsy.